-- "All Aboard the Magic (Science) Bus" in Community Giving
-- More Than Half of Nevada's 10th Graders Will Perform At or Below
Proficiency Levels in Science
-- The Samaritan Innovative Science Foundation is Trying to Change
Science Proficiency Levels
LAS VEGAS, Sept. 8, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, and The Samaritan Innovative Science Foundation (The Samaritan Foundation), a 501 (c)(3) nonprofit sponsored by Samaritan, is pleased to announce today's issue of IN BUSINESS, Las Vegas, (Community Giving) highlights Samaritan's charitable giving with its efforts to get BioFutureBus (Science Laboratory) rolling to help the community Samaritan calls home.
http://www.samaritanpharma.org/ibarticle.pdf
Dianne Thompson, SVP of the Samaritan Foundation stated, "We are extremely flattered by this recognition and look forward to the day the BioFutureBus is really making a difference in a child's perception of science in Las Vegas and then hopefully, we can bring this concept to other communities nationwide."
About The Samaritan Innovative Science Foundation
The Samaritan Innovative Science Foundation (The Samaritan Foundation) is a 501(c)(3) nonprofit organization founded in 2003 by Dr. Janet Greeson, CEO, and Eugene Boyle, CFO of Samaritan Pharmaceuticals (AMEX:LIV). The Foundation's focus and passion is to meet the unmet medical and social needs of children. For additional information, visit http://www.samaritanpharma.org/.
Samaritan Pharmaceuticals: "We LIV... to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics for AIDS, Alzheimer's, cancer and heart disease patients. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2006. The company undertakes no duty to update forward-looking statements.